536974-94-4

Usage

Uses

Used in Pharmaceutical Industry:
[4-(benzyloxy)-3-fluorophenyl]methanol is used as a key intermediate in the synthesis of various drugs. Its unique structure, including the fluoro-substituted phenyl ring and the benzyloxy side chain, contributes to the development of new pharmaceutical compounds with specific therapeutic properties.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, [4-(benzyloxy)-3-fluorophenyl]methanol serves as an intermediate for the production of agrochemicals. Its incorporation into these products can enhance their effectiveness in agricultural applications, such as pest control and crop protection.
It is crucial to handle and store [4-(benzyloxy)-3-fluorophenyl]methanol with appropriate safety measures, given its potential flammability and the risks associated with ingestion or inhalation.

Upstream product

• 100-39-0 benzyl bromide 
• 1379604-20-2 benzyl-4-(benzyloxy)-3-fluorobenzoate 
• 350-29-8 3-fluoro-4-hydroxybenzoic acid 
• 405-05-0 3-fluoro-4-hydroxybenzaldehyde 
• 175968-61-3 3-fluoro-4-[(phenylmethyl)oxy]benzaldehyde 

Downstream Products

• 536974-95-5 benzyl 4-(chloromethyl)-2-fluorophenylether 
• 1260389-37-4 4-(((6-cyanobiphenyl-3-yl)(4H-1,2,4-triazol-4-yl)amino)methyl)-2-fluorophenyl sulfamate 
• 1260389-55-6 5-((3-fluoro-4-hydroxy-benzyl)(4H-1,2,4-triazol-4-yl)amino)biphenyl-2-carbonitrile 
• 1268821-52-8 5-((4-(benzyloxy)-3-fluoro-benzyl)(4H-1,2,4-triazol-4-yl)amino)biphenyl-2-carbonitrile 
• 922719-77-5 4-benzyloxy-3-fluorobenzylbromide 
• 537677-52-4 4-[(4-benzyloxy-3-fluorobenzyl)[1,2,4]triazol-4-ylamino]benzonitrile 
• 537677-53-5 4-[(3-Fluoro-4-hydroxy-benzyl)-[1,2,4]triazol-4-yl-amino]-benzonitrile 

Relevant academic research and scientific papers

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

Stereoselective radiosynthesis of L- and D-3-[18F]fluoro-α-methyltyrosine

A three-step radiosynthesis is described which allows for the first time the preparation of L- and D-3-[18F]fluoro-α-methyltyrosine starting from [18F]fluoride. Corresponding 3-fluoro-4-formyl-benzylated Sch?llkopf derivatives were

AROMATASE INHIBITOR

There is provided a compound of formula (I) wherein Z is selected from N and CR22, wherein R22 is H or a bond with D, wherein D is selected from a bond, C=O, and linear or branched hydrocarbon groups having a carbon chain of from 1 t

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

The invention relates toa pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the trea

Dual aromatase-steroid sulfatase inhibitors

By introducting the steroid sulfatase inhibitory pharmacophore into aromatase inhibitor 1 (YM511), two series of single agent dual aromatase-sulfatase inhibitors (DASIs) were generated. The best DASIs in'vitro (JEG-3 cells) are 5, (IC50(aromatase) = 0.82 nM; IC 50(sulfatase) = 39 nM), and 14, (IC50(aromatase) = 0.77 nM; IC50(sulfatase) = 590 nM). X-ray crystallography of 5, and docking studies of selected compounds into an aromatase homology model and the steroid sulfatase crystal structure are presented. Both 5 and 14 inhibit aromatase and sulfatase in PMSG pretreated adult female Wistar rats potently 3 h after a single oral 10 mg/kg dose. Almost complete dual inhibition is observed for 5 but the levels were reduced to 85% (aromatase) and 72% (sulfatase) after 24 h. DASI 5 did not inhibit aldosterone synthesis. The development of a potent and selective DASI should allow the therapeutic potential of dual aromatase-sulfatase inhibition in hormone-dependent breast cancer to be assessed.

METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES

The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for